Eli Lilly & Co. (LLY) Raises Quarterly Dividend 2% to $0.51; 2.4% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- SanDisk shares fall on election and chip sector pressure
- Seagate Technology shares drop amid sector selloff
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
Lilly (LLY) Shows Incremental Growth Opportunities - Piper Jaffray
December 9, 2015 7:42 AM ESTPiper Jaffray analyst, Richard Purkiss, attended a Eli Lilly (NYSE: LLY) investor day specifically addressing Elanco, its animal heath business, and its Alzheimer's disease portfolio. He came away with a deeper understanding of Elanco's growth drivers and believes this business could spur upgrades from other banks. Also, the depth and breadth of LLY's Alzheimer's portfolio beyond solanezumab was a clear upside surprise.
The wider animal health... More



